Session Idle Alert

You will be logged out in due to inactivity. Please click Ok to extend the session or select Log Out to end the session.

NFLIS-DRUG 2020 MIDYEAR REPORT FINDINGS:

Top 25

Most Frequently Identified Drugs Submitted to laboratories from January 1, 2020, through June 30, 2020, and analyzed by June 30, 2020.

279 98.5%

DISTINCT DRUG CASES SUBMITTED TO STATE AND LOCAL LABORATORIES DURING THE FIRST HALF OF 2020

355,104

Drug cases during the first half of 2020 identified an estimated 612,426 drug reports.

Methamphetamine was the most frequently identified drug (29%). Fentanyl was the third most frequently identified drug and most frequently reported prescription drug. 5F-MDMB-PICA was the most frequently reported synthetic cannabinoid.

Link to midyear report

5 New NFLIS-DRUG Reports

The following 5 drugs were reported for the first time between October 1, 2020 and December 31, 2020:

  • 4F-MDMB-BUTICA
  • 2Br-4,5-Dimethoxyphenethylamine
  • 4F-3-Methyl-alpha-PVP
  • 5F-EMB-PICA
  • Metonitazene

NFLIS-Drug Snapshot (June 2020)

NFLIS began in September 1997 as a single data collection effort of drug chemistry analysis results from local, State, and Federal forensic laboratories (now called NFLIS-Drug). These laboratories analyze substances secured in law enforcement operations across the country. Since its inception, NFLIS-Drug has become an operational information system that includes data from forensic laboratories that conduct analyses of about 98 percent of the Nation's approximate 1.5 million annual drug cases. As of February 2021, NFLIS-Drug includes voluntary participation from 50 State systems and 110 local or municipal laboratories/laboratory systems, representing a total of 286 individual laboratories. The NFLIS program is expanding the scope of data collection to include public and private toxicology laboratory data on toxicological findings from antemortem and postmortem drug testing (NFLIS-Tox) and medical examiner and coroner office data regarding deaths in which drugs were identified (NFLIS-MEC). NFLIS-Tox recruitment is currently underway with over 70 laboratories signing on to participate. NFLIS-MEC recruitment will begin in the Fall of 2021.

NFLIS-Drug provides the community with midyear and annual reports highlighting trends in seized drug data submitted to and analyzed by laboratories. Special reports and briefs respond to national drug crises such as fentanyl and fentanyl-related compounds, and synthetic cannabinoids and synthetic cathinones. The NFLIS-Drug Snapshots highlight new and emerging drugs, and the public data tables show drug reports by state from 2007-2019.

If your laboratory would like to participate in NFLIS, review DEA's FAQs document to determine your entity's eligibility to participate in NFLIS and to review other information about each NFLIS component and the next steps for participation. You may also contact DEA at DEANFLIS@rti.org.

Participating Laboratories, by U.S. Census Region